Clinical Trial Update: Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) [Phase 2]

View source ↗

Summary

Phase 2 bridging trial comparing V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to the Butantan Dengue Vaccine (DV) in healthy adults, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Butantan Dengue Vaccine (DV)
• V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated])

Snippet

Sponsor: Butantan Institute | Conditions: Dengue | Phase 2 | Status: COMPLETED | Results posted: 2025-11-18